A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes (NCT07112872)
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus
🩺 Plain-English Summary (8th-Grade Level)
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (10 items).
Location: Arizona Liver Health - Tucson — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D
- Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening
- History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment
- Evidence of clinically significant/active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea)
- Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors
- Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome)
- Have a known, clinically significant gastric emptying abnormality
- Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension
- Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Arizona Liver Health - Tucson — Tucson, Arizona
- Orange County Research Center — Lake Forest, California
- Prospective Research Innovations Inc. — Rancho Cucamonga, California
- Encompass Clinical Research — Spring Valley, California
- Chase Medical Research — Waterbury, Connecticut
- Emerson Clinical Research Institute — Washington D.C., District of Columbia
- K2 Medical Research South Orlando, LLC — Clermont, Florida
- Center for Diabetes, Obesity and Metabolism Inc — Pembroke Pines, Florida
- Rophe Adult and Pediatric Medicine/SKYCRNG — Union City, Georgia
- Accellacare of Duly Health and Care — Oak Lawn, Illinois
- Mercury Street Medical Group, PLLC — Butte, Montana
- Neurobehavioral Research, Inc. — Cedarhurst, New York
- Accellacare of Piedmont Healthcare — Statesville, North Carolina
- Accellacare of Wilmington, LLC — Wilmington, North Carolina
- NexGen Research — Lima, Ohio
- Tristar Clinical Investigations — Philadelphia, Pennsylvania
- Alliance for Multispecialty Research. LLC — Knoxville, Tennessee
- Clinical Research Associates — Nashville, Tennessee
- Texas Diabetes & Endocrinology, P.A. — Austin, Texas
- Apex Mobile Clinical Research — Bellaire, Texas
- Velocity Clinical Research — Dallas, Texas
- Velocity Clinical Research (Impact Research Institute) — Waco, Texas
- Chrysalis Clinical Research — St. George, Utah
- Manassas Clinical Research Center — Manassas, Virginia
- Obudai Egeszsegugyi Centrum Kft. — Budapest,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 2 Diabetes Mellitus
- Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
- Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
- Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System — Los Angeles, California
- A Study of Glycemic Control in Left Ventricular Assist — Rochester, Minnesota
- Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus — Mesa, Arizona
Explore by condition: All Type 2 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.